Relmada Therapeutics (RLMD) News
NASDAQ: RLMDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RLMD news summary
We found 5 recent headlines mentioning Relmada Therapeutics (RLMD): 2 in the past week and 5 in the past 30 days, most often from GlobeNewswire, Nasdaq. RLMD is making an outsized move today, down 15.76% at $2.62, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Relmada Therapeutics, Inc. Appoints Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer", was published by Nasdaq on Nov 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Relmada Therapeutics headlines
- Relmada Therapeutics, Inc. Appoints Jørn Skibsted Jakobsen, MD, PhD, as Chief Development OfficerRelmada Therapeutics, Inc. announced the appointment of Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology, on November 16, 2026. Dr. Jakobsen will lead…Nasdaq
- Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development OfficerFormer ADSTILADRIN® global clinical development leader brings extensive uro-oncology expertise as Relmada prepares to initiate the Phase 3 SPECTRUM program for NDV-01 Former ADSTILADRIN® global…GlobeNewswire
- Relmada (RLMD) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Relmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in LondonCORAL GABLES, Fla., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for…GlobeNewswire
- Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026CORAL GABLES, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for…GlobeNewswire